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What roles do astrocytes play in human disease? This question remains unanswered
for nearly every human neurological disorder. Yet, because of their abundance and
complexity astrocytes can impact neurological function in many ways. The differentiation
of human pluripotent stem cells (hPSCs) into neuronal and glial subtypes, including
astrocytes, is becoming routine, thus their use as tools for modeling neurodevelopment
and disease will provide one important approach to answer this question. When
designing experiments, careful consideration must be given to choosing paradigms for
differentiation, maturation, and functional analysis of these temporally asynchronous
cellular populations in culture. In the case of astrocytes, they display heterogeneous
characteristics depending upon species of origin, brain region, developmental stage,
environmental factors, and disease states, all of which may render experimental results
highly variable. In this review, challenges and future directions are discussed for using
hPSC-derived astroglial progenitors andmature astrocytes for neurodevelopmental studies
with a focus on exploring human astrocyte effects upon neuronal function. As new
technologies emerge to measure the functions of astrocytes in vitro and in vivo, there
is also a need for a standardized source of human astrocytes that are most relevant to the
diseases of interest.
Keywords: human stem cells, astrocytes, RASopathies, disease models, synaptogenic proteins, neurological
disorders, regenerative medicine, developmental disorders of the brain
INTRODUCTION
With the recent technological advances for astrocyte manipula-
tion, generation, purification, and functional analyses in normal
and diseased states, there is a need for standardization and opti-
mization of the experimental system. In regards to this review,
the system of interest is the differentiation of astrocytes from
human pluripotent stem cells (hPSCs), either embryonic stem
cells (ESCs) or induced pluripotent stem cells (iPSCs). During
neurodevelopmental studies, it would be ideal to compare cell dif-
ferentiation of control and experimental groups beginning with
limited differences except for the variable of interest. Inevitably,
epigenetic variations will exist within the hPSC lines prepared
from different cellular origins (Kim et al., 2010) and those cul-
tured with different methods (Nazor et al., 2012; Tomoda et al.,
2012), all of which may lead to altered differentiation potentials.
Also, genetic variability will always occur among human cellular
sources, which has led to the design of methods for generating
isogenic control hPSC lines through genetic correction technol-
ogy (Zwaka and Thomson, 2003; Hockemeyer et al., 2009, 2011).
These technologies (e.g., homologous recombination, zinc fin-
ger nucleases, and TALENS) are designed to target and replace
a mutation of interest with wild-type sequence while keeping
the rest of the genome unmodified. In the subsequent stage
of directed neural induction and differentiation of hPSCs into
neuroepithelia/neural stem cells (NSCs), multiple protocols have
been designed with varying environmental factors and techniques
which can alter the developmental timing and identity of the final
cell type of interest [for example, the generation of CNS neural
cells (Zhang et al., 2001) vs. PNS (Lee et al., 2007)]. Although
variability has the advantage of masking non-specific phenotypes
in disease models, and is also a better representation of variation
in nature, it may lead to false positive experimental results when
using a low number of replicates. While keeping in mind this het-
erogenous sourcematerial, we will focus this review on examining
the variability and heterogeneity that occurs between the stages
from hPSC-derived NSCs to astrocytes, and discuss the advan-
tages and disadvantages of using an in vitro system to enumerate
major experimental variables that should be taken into account
when designing disease-related studies.
For which neurological diseases is an examination of astrocyte
function relevant? There are numerous methods to mimic disease
states in cultured astrocytes including scratch assays (Yang et al.,
2012), mechanical stretch (Wanner et al., 2008), and treatments
with inflammatory factors (Falsig et al., 2004), but the main
benefit of using patient-specific iPSCs is to study specific disease-
causing genetic mutations. The most obvious disorder to target is
Alexander Disease, which is referred to as a “primary astrocyte
disease” because it is caused by mutations of the semi-specific
astrocyte protein GFAP, but also eventually leads to damage in
oligodendrocytes and neurons through yet unknownmechanisms
(Messing et al., 2012). On the other hand, it is becoming clear
that many, if not all, neurodevelopmental and neurodegenerative
diseases may be directly or indirectly affected by glial function
(Molofsky et al., 2012; Verkhratsky et al., 2012). Whether the
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observed astrocytic phenotypes are disease-specific or generic
consequences of a stressed “reactive” astrocyte (referred to here
as astrogliosis) that contributes downstream to neighboring cells
is a major question that should be examined in each case. For
example, it has been observed in some amyotrophic lateral sclero-
sis models that astrocytes either secrete toxic factors [i.e., lipocalin
2 (Bi et al., 2013)] or have a deficiency in providing support to
motoneurons, leading to neuronal degeneration. Whether these
factors are the main cause of motoneuron loss and how they
specifically affect these neurons is still not clear (Sica, 2012;
Phatnani et al., 2013). In the case of neurodevelopmental dis-
orders, an altered timing of astrocyte differentiation likely leads
to changes in the number of adult astrocytes and/or in their
impact upon neurons, as described in more detail below. For the
purposes of this review, we will provide examples for experimen-
tation using one of the most common classes of neurodevelop-
mental disorders that are likely affected by both developmental
and functional changes in neural cells. These syndromes are
commonly referred to as “RASopathies” because they all involve
alterations in the Ras/MAPK signaling pathway and lead to men-
tal impairments among other phenotypes (Tidyman and Rauen,
2009). Mouse models have shown that astrocyte progenitors have
an accelerated development and/or proliferation in a number of
these syndromes including Noonan syndrome (Gauthier et al.,
2007), Neurofibromatosis-1 (Hegedus et al., 2007), Costello syn-
drome (Paquin et al., 2009), and cardiofaciocutaneous syndrome
(Li et al., 2012; Tien et al., 2012), though the astrocyte-specific
functional consequence on neurons in these contexts, especially
in a human cellular system, is unknown.
What phenotypes should be examined? There are at least
three major levels of cellular examination that can be addressed
when comparing diseased and control astrocytes; (1) intrin-
sic changes within an individual cell such as gene expres-
sion and cell signaling, (2) population networks that include
heterogeneous cell types and long range coupling, and (3)
extrinsic factors released from astrocytes that affect other cell
types including neurons, oligodendrocytes, microglia, or those
that make up the vasculature. These levels are also temporally
dynamic during differentiation and the functional consequences
may depend on development, brain region, and environmen-
tal conditions (Zhang and Barres, 2010; Oberheim et al., 2012;
Theis and Giaume, 2012). In some cases the appropriate choice
of analysis is obvious when the specific cause of disease is
known, i.e., astrocytes from an ALS model (mutant TDP-43)
iPSC lines have an increased expression and mislocalization
of TDP-43 protein (Serio et al., 2013), and astrocytes from
Alzheimer’s disease models (sporadic cases and mutant APP)
have Aβ oligomer accumulation (Kondo et al., 2013). Though
for the majority of other cases, finding a disease-related phe-
notype may take various large scale profiling methods. Below,
using examples with RASopathy-specific cells, we will discuss the
advantages and shortcomings of utilizing hPSC-derived astro-
cytes to study specific functional aspects both intrinsically and
upon other cell types. Ultimately, the phenotypes should be
confirmed in an in vivo environment with methods such as
transplantation of the human astrocytes into rodent or primate
brain.
CONSEQUENCES OF FITTING A STELLAR UNIVERSE
IN A DISH
One major advantage of studying in vitro astrocyte progenitor
differentiation from NSCs in a culture system is that the intrin-
sic developmental order (neurons, then glia) and timing (several
months for human) correlates with in vivo development, due
to a combination of transcriptional and epigenetic regulations
(Sauvageot and Stiles, 2002; Okano and Temple, 2009). For devel-
opmental studies, this extended temporal program allows for
human cellular profiling during differentiation at the gene expres-
sion (qPCR, microarray, RNA-seq), protein (immunocytochem-
istry, Western, proteomics), and epigenetic (methylation, histone
modifications) levels at discrete stages (Krencik and Zhang, 2006).
During RASopathy studies, this profiling could be used to deter-
mine whether abnormal Ras/MAPK signaling cause temporal
shifts in astrogliosis, as observed in mouse models, and these data
sets can provide baselines for comparisons after genetic or drug
screening with the aim of modifying the abnormal developmental
timing back to control levels. For example, cells may be acutely or
chronically treated with compounds safe for clinical trials includ-
ing inhibitors of farnesyl transferase,MEK, and ERK (Rauen et al.,
2011), or expression levels may be hampered with siRNA tech-
nologies. One should bear in mind that one major drawback is
that the population of neural progenitors derived from hPSCs are
non-synchronous, e.g., there will always be a mixture of cells at
slightly different stages of development (Figure 1). On the other
hand, this phenomenon may have some silver linings. For exam-
ple, three-dimensional differentiation of neuronal cultures in a
cluster generates cells intrinsically organized in a spatial and tem-
poral polarization that mimics radial glial and neuronal layering
in the cortex (Eiraku et al., 2008), potentially producing a more
accurate model of in vivo development. This structural recapit-
ulation may also occur during astroglial differentiation although
it has not been extensively investigated. With an in vitro system
it is possible to recapitulate normal development by examining
the temporal expression pattern of progenitor (NFIA, S100B)
and more mature (GFAP) markers over time (Krencik et al.,
2011). The scarcity of astrocyte markers does not yet allow for
more precise examination of subtypes that occur throughout the
CNS (one likely exemption are regionally-specific developmental
transcription factors), but it may be possible to recapitulate the
distinct morphological characteristics displayed by human astro-
cytes in vivo, which depends on their cortical location (Oberheim
et al., 2009).
Perhaps the most important pressing issues in this field are
how to properly identify a mature astrocyte and how to stan-
dardize this definition between research laboratories. GFAP has
long been the gold standard as an astrocyte marker (Eng et al.,
2000), even though its levels change during development, aging,
and stress. At what point should a glial progenitor cell be termed
an astrocyte using this marker? For immunocytochemical analy-
sis, the appearance of GFAP protein is commonly used since there
are many commercially available antibodies that consistently
work well and the cellular protein content is highly abundant.
Unfortunately, during early stages of the hPSC differentiation
process, GFAP can be observed diffusely throughout the cells
with high antibody concentrations and high exposure times, then
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FIGURE 1 | Astroglial differentiation from human pluripotent stem cells allows for the investigation into neurodevelopmental and functional aspects
of neurological and neurocognitive disorders in culture or after engraftment into intact nervous tissue.
gradually localizes in a filamentous pattern while becoming more
intense (Krencik, pers. observation), thus the identification of an
astrocyte using GFAP as a marker is not absolute. Other pro-
teins used as markers also display shifting localization as the
cells mature, for example CD44 localizes in a punctuate/ruffled
manner after the receptor inserts into the cell surface mem-
brane. Thus, standards for identifying onset of these markers
may be unknowingly disparate among research groups that have
thus far generated hPSC-derived astroglial progenitors for stud-
ies (Krencik et al., 2011; Gupta et al., 2012b; Juopperi et al., 2012;
Serio et al., 2013; Shaltouki et al., 2013;Wang et al., 2013), leading
to examination of cells at different developmental stages, levels of
astrogliosis, or may even falsely identifying non-neural contami-
nating cells which can appear in this culture system (Krencik and
Zhang, 2011). One suggestion for standardizing identification is
to first measure primary astrocyte cultures that usually contain
GFAP+ and GFAP- cells to determine maximum and minimum
cutoffs during imaging, and then assemble information on the
relative intensity of filamentous GFAP for each individual cell in
an imaging field. Unfortunately, other astrocyte-specific markers
such as Glt-1 and Aldh1L1 are more difficult to use for immuno-
chemistry (Krencik, pers. observation) and less is known about
their expression in human cells, yet tools based on these markers
are effective reporters in mouse transgenic studies (Yang et al.,
2011). Likewise, S100B is a useful progenitor marker, but it is
also expressed in oligodendrocyte progenitors (Deloulme et al.,
2004) and NG2 cells (Hachem et al., 2005). The pressing need
to identify more markers of both rodent and human astrocytes
to further investigate these cells under various conditions is evi-
dent. Ultimately, hPSC-derived astrocytes should be identified
by astrocyte-specific functional outputs, but traditional readouts
such as glutamate uptake and promotion of synaptogenesis are
also functions of progenitor cells and other glial types to differing
extents.
Unfortunately for researchers interested in generating puri-
fied clonal mature astrocytes as quickly as possible for functional
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studies, the prolonged developmental timeline of this het-
erogenous culture system mentioned above (approximately 4–6
months depending on the protocol used) is an inconvenience.
The astrocyte differentiation process can be accelerated by pro-
longed treatment with gliogenic factors including CNTF, BMP,
and LIF, or possibly by imposing epigenetic changes to occur
(Gupta et al., 2012a). However, these treatments could have some
effect upon disease phenotypes or even mask them. To date, no
systematic comparison has been made of astroglial cells derived
from the same starting material with differing methods. For a
more temporally pure population it may be possible to clonally
culture and expand a single cell, although proliferation of human
astrocytes appears to be density dependent (Krencik, pers. obser-
vation). Other possible options are to cell-sort progenitors based
on distinct cell type markers as has been done with CD44 (Yuan
et al., 2011) or to transform fibroblasts directly into astrocytes
using transcriptional codes similar to what has been done for
the transdifferentiation of human fibroblasts to neurons (Pang
et al., 2011). Regardless of the techniques used, methods should
be considered that most accurately produce the cell type of inter-
est for disease studies and detailed method descriptions should be
provided for repeatability and data comparison between research
groups.
It is understood in quantummechanics that any observation of
a system will have some change on the system itself, thus affecting
the final measurement. In cellular neuroscience, we obviously dis-
turb the cellular order by designing simplified models outside of
the natural state. The major shortcoming of using hPSC-derived
neural cells (and primary cultures from rodent or human origin)
for disease modeling is the changes that occur in culture, which
is usually a more stressful environment compared to the nor-
mal in vivo nervous system. Yet, the use of cultured cells confers
many advantages including cell type purity, control of environ-
mental factors, and easy access for experimentation. Astrocytes
were first cultured from early postnatal rodent brain by tak-
ing advantage of their adhesiveness, survivability, and enhanced
growth rates compared to other neural types while cultured in
serum conditions (McCarthy and de Vellis, 1980) or after sub-
sequently switching to serum-free defined conditions (Morrison
and de Vellis, 1981). Serum varies between batches and leads to
changes in morphological and proliferative properties, and there-
fore it is not suggested for use with primary astrocyte cultures;
yet many studies are still conducted in serum containing con-
ditions for its ease of use. More recently, an immunopanning
technique has been designed for a rapid serum-free purifica-
tion, revealing major gene expression changes in the presence of
serum (Foo et al., 2011). High serum also affects hPSC-derived
astrocytes in their morphology, adhesiveness, proliferation, and
usually results in the expansion of non-neural contaminants at
early differentiation stages (Krencik, pers. observation). Another
stressor is that cells are typically cultured at higher oxygen lev-
els than physiological conditions, which may impact progenitor
proliferation and/or differentiation (Studer et al., 2000). The
choice of culture media and additives will likely affect the differ-
entiation process as well. For example, long term expansion of
human NSCs requires the presence of growth factors such as EGF
and FGF2 (Caldwell et al., 2001), but variability in the starting
concentrations and metabolism of these factors, and the time
between media replacement, will likely be inconsistent between
different cultures and researchers. One advantage of using these
growth factors is that for RASopathy studies the presence of these
factors directly activates the Ras/MAPK pathway through receptor
tyrosine kinase receptors, thus this pathway is chronically stimu-
lated and may expose disease-related phenotypes. Taken together,
although these culture factors may produce a system that is dis-
similar to the natural environment, the stressful conditions may
accelerate or expose disease phenotypes that normally do not
appear until adulthood in humans and evolve over years such as
neurodegenerative diseases. Even though all neurodegeneration-
related phenotypes will be unlikely to be present in this rela-
tively short-term culture system, cellular phenotypes have been
observed with Parkinson’s disease (Devine et al., 2011; Nguyen
et al., 2011) and ALS cellular models (Bilican et al., 2012). It is
important to note that even after astrocytes are generated, semi-
purified, and prepared for experimentation using the method of
choice, the issue still remains as to whether the final product is the
best functional model for the disease of interest.
HOW TO TRAVERSE THIS DIVERSE MULTIVERSE
For modeling region-specific diseases in vitro, the most relevant
cell subtype to generate is one that displays similar dysfunc-
tional properties as cells in the natural disease system. Precise
directed differentiation of specific neuronal subtypes from hPSCs
is increasingly attainable due to the ease of subtype identifi-
cation using expression of neurotransmitter-related factors as
markers; for example, observing the presence of choline acetyl-
transferase in motoneurons (Li et al., 2005), tyrosine hydroxylase
in dopaminergic neurons (Zeng et al., 2004) or GABA in striatal
interneurons (Aubry et al., 2008). Though astrocytes are known
to secrete various gliotransmitters including ATP and D-serine,
these are unlikely ideal markers because questions still remain
about the physiological role of gliotransmission due to possi-
ble experimental artifacts including astrogliosis (Agulhon et al.,
2012), and whether these gliotransmitters are variably expressed
between subtypes. However, it is known that astrocytes display
heterogenous enzymatic activities (Hansson, 1984) and responses
to neurotransmitters in regionally distinct subtypes, correlating
with their adjacent neuronal subtypes (Matyash and Kettenmann,
2010; Oberheim et al., 2012). Since hPSC-derived NSCs can be
regionally specified at the neuroepithelia stage by the application
of morphogens and then further matured into neurons or glia
that maintain this identity (Liu and Zhang, 2011), regional dis-
tinctions that can be measured in vivo may also occur in vitro
if these functions are endowed through intrinsic mechanisms.
For example, the promoter activity for the astrocyte specific
glutamate transporter Glt-1 is lower in spinal cord astrocytes
compared to those in the brain (Regan et al., 2007) and the
inward rectifying potassium channel Kir4.1 protein is more abun-
dant in ventral spinal cord compared to dorsal regions (Olsen
et al., 2007). Morphology and proliferation rates are also region-
specific (Emsley and Macklis, 2006). In vitro, it has been shown
that astrocytes prepared from different regions exhibit differen-
tial effects upon neurons including neuronal outgrowth (Qian
et al., 1992), dendritic arborization (Le Roux and Reh, 1995),
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and differentiation (Castelo-Branco et al., 2006). Whether
these functional distinctions can be recapitulated by hPSC-
derived astrocytes specified to distinct subtypes is still unknown.
Together, some of these specific markers and functions may be
useful for identification after directed differentiation of hPSCs
toward the distinct type of interest.
Does astrocyte regional heterogeneity have relevance for dis-
ease studies? In vivo, the degree of astrocytic responses in disease
states may be due to both intrinsic diversity and responses to
the local environment. For example, midbrain astrocytes may
respond differentially to changes in dopamine levels in early stages
of Parkinson’s disease due to variableMAO-B levels (Mallajosyula
et al., 2008; Vaarmann et al., 2010) and spinal cord astrocytes
may not be able to properly reduce glutamate levels during
ALS-induced excitotoxicity due to a low level of Glt-1 (Regan
et al., 2007). This heterogeneity also has relevance for regen-
erative medicine. Midbrain astrocytes can secrete neurotrophic
factors that protect dopaminergic neurons from degeneration
including GDNF and CDNF (Lin et al., 1993; Lindholm et al.,
2007), although these factors are also expressed in other regions.
Developmental studies have revealed that astrocyte functional
diversity may at least partially depend on their domain of origin.
For example, dorsally and ventrally located astrocyte progen-
itors differentially express the guidance cues Slit1 and Reelin
(Hochstim et al., 2008) and the extracellular matrix protein
tenascin C (Karus et al., 2011). It is unknown whether these
differences also depend on environmental cues, though it is
interesting that astrocytes continue to occupy their distinct sub-
regional domains determined in development and do not migrate
to other domains after injury or depletion of adjacent cells (Tsai
et al., 2012). With regards to RASopathy modeling, astrocytomas
in NF1 predominantly occur around or near the optic nerve, thus,
it may be most relevant for cancer studies to direct hPSCs to the
optic stalk neuroepithelium, the probable source of optic nerve
astrocytes (Horsburgh and Sefton, 1986). Though it is unknown
why gliomas preferentially occur in the optic nerve, there is evi-
dence of heterogenous astrocyte expression of NF-1 (Yeh et al.,
2009), region specific effects of NF1 on astrocyte differentiation
(Lee da et al., 2010), subtype astrogliosis (Rizvi et al., 1999)
and differential responses from the local environment (Simmons
et al., 2011) which may all play some role. As another example,
abnormal vision is very common in Noonan syndrome including
refractive errors (Sharland et al., 1992), therefore astrocytes dif-
ferentiated from hPSC-derived retinal and optic nerve progenitor
cells (Lamba et al., 2006; Meyer et al., 2009; Nakano et al., 2012)
may be a promising candidate for investigation.
Another important variable to consider includes the matura-
tion state of the astrocyte. hPSC-derived astrocytes are likely a
mix of NSCs and astroglial progenitors during the differentia-
tion process as described above (Figure 1), makingmeasurements
of mature functions variable in this mixed culture system. At
the genomic level, astrocytes isolated at different stages of devel-
opment differ in expression of numerous genes (Cahoy et al.,
2008). Even after further maturation of hPSC-derived astrocytes
in prolonged culture, these cells are likely immature compared to
human adult astrocytes since they have been differentiating for
only a few months and have not received signals from neurons
that are known to affect astrocyte-specific proteins (Stipursky
et al., 2012). For example, the Glt-1 protein remodels its local-
ization near neighboring neuronal synapses during development
(Benediktsson et al., 2012). Conversely, immature astrocytes may
be better suited for studying synaptogenesis because immature
astrocytes, but not mature, secrete the synaptogenic factor throm-
bospondin (Christopherson et al., 2005). It has also been revealed
that developing and adult astrocytes functionally differ based on
differential expression of glutamate receptors (Sun et al., 2013).
Importantly, the key factor in modeling disease is that after gen-
erating the most relevant cell of interest, it would be critical to
determine whether these cultured hPSC-derived astrocytes are
exhibiting distinct responses to specific disease paradigms or
whether they are only displaying generic responses independent
of the stress paradigm (i.e., increases in oxidative stress, ER stress,
or cell death), though there is now evidence of specific tran-
scriptional changes that occur depending on the type of astrocyte
stimulus (Lavisse et al., 2012; Zamanian et al., 2012).
EXTRACELLESTIAL CONTACT
Even though cultured astrocytes imperfectly recapitulate cells
in the brain environment as discussed above, the use of cul-
tured primary astrocytes has been instrumental in elucidating
their influence on other cell types in both normal and dis-
eased conditions, as thoroughly reviewed elsewhere (Lange et al.,
2012). Importantly, the use of human-specific astrocytes from
hPSCs may uncover unique phenotypes, including those that
are known to exist in vivo (Oberheim et al., 2009), which can
be masked in non-human backgrounds or otherwise difficult
to measure due to limited resources of human tissue. In the
case of RASopathies, immunochemical analysis with human NF1
brains has revealed an increase of astrogliosis, though how this
contributes to neuronal abnormalities is unknown (Nordlund
et al., 1995). Structural MRI studies of Costello syndrome brains
usually uncover macrocephaly, ventriculomegaly, and Chiari 1
malformation which suggests an increase of astrocyte progenitor
number (Gripp et al., 2010) similar to what has been observed
in mouse models. Another experimental option for human cel-
lular studies is use of human fetal NSCs for analysis. Recent use
of this system has revealed that the Ras/MAPK pathway may be
dysregulated in both Fragile X and Down syndrome genetic back-
grounds (McMillan et al., 2012); suggesting this pathway plays
a major disease role outside of RASopathies. In light of these
issues, the use of hPSC-derived astrocytes would be a convenient
human specific system to study intrinsic changes in RASopathy
genetic backgrounds including astrogliosis and/or proliferation.
Besides intrinsic cellular changes, disease modeling can shed light
on what factors diseased astrocytes bestow upon other cells types.
Because it is difficult to separate the effects of specific cell types
in vivo, the system can be used for identifying these factors in
either coculture, with use of astrocyte conditioned media (ACM),
or transplantation studies (Figure 1).
Astrocytes receive and send signals to numerous cell types
throughout the nervous system; thus simplified coculture sys-
tems may be a means to reveal important signaling components
while optimizing additional extrinsic factors. One major route
of communication apt for examination is between the brain
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vasculature system and astrocytic end feet (termed the gliovas-
cular unit) which plays diverse roles in normal and diseased
states. These functions include the coupling of neuronal activity
to blood flow regulation and maintenance of the blood-brain-
barrier (BBB) (Iadecola and Nedergaard, 2007; Kovacs et al.,
2012). In order to study the effect of astrocytes on BBB forma-
tion and maintenance, numerous direct and indirect co-culture
systems have been designed for studies with brain endothelial
cells, as extensively reviewed elsewhere (Naik and Cucullo, 2012;
Lippmann et al., 2013), although the specific molecules they pro-
vide is unclear. In the other direction, cultured endothelial cells
induce astrocyte differentiation possibly through LIF secretion
(Mi et al., 2001). Astrocytes also play major roles in synapto-
genesis and synaptic plasticity (Allen and Barres, 2005; Eroglu,
2009; Barker and Ullian, 2010). Astrocyte-neuronal cocultures
and/or ACM have been used to uncover numerous synaptogenic
factors released by astrocytes which include cholesterol (Mauch
et al., 2001), TNFα (Beattie et al., 2002), thrombospondins,
(Christopherson et al., 2005), Hevin, Sparc (Jones et al., 2011;
Kucukdereli et al., 2011), and glypicans (Allen et al., 2012). How
these and other factors that alter synaptic plasticity [including
extracellular matrix molecules and cytokines (Wiese et al., 2012)]
change during development and disease in human cellular back-
grounds are unclear. One method to investigate these changes
may be quantitative secretomics via mass spectrometry as has
been conducted with mouse astrocytes (Dowell et al., 2009; Jha
et al., 2012). Simplified coculture studies between differing cell
types may lead to discovery of drug targets to inhibit or activate
these specific signaling pathways, as has been conducted in the
case of a thrombospondin receptor (Eroglu et al., 2009).
Ultimately, cell–cell interactions should be studied in a more
natural environment for proper cell–cell communication to limit
astrogliosis and provide the human astrocytes with extracellu-
lar matrix factors (Figure 1). One potential experimental model
system includes hippocampal slice cultures, which have been
previously used from human epilepsy patient tissue to measure
functional changes in astrocytes (Hinterkeuser et al., 2000). Since
live human brain tissue is rarely available for other neurological
Table 1 | Atlas for using hPSC-astrocytes in normal and disease states.
Stages Challenges Recommendations
hPSCs Heterogeneity between lines Use similar source material (cell type, age of donor, passage number, etc.)
Use non-integrative reprogramming
Generate control lines with pharmacological or genetic correction technology
Neuroepithelia/NSCs Regional heterogeneity Generate/select for CNS-specific cells instead of PNS neural crest
Specify to distinct dorsal-ventral and anterior-posterior axis if needed
Astrocyte progenitors Stressful culture environment Use serum free conditions plus additives such as antioxidants
Lower oxygen conditions, avoid acidity
Limit stress during passaging
Non-synchronous mixed culture Cell sort if purification is desired
Mature long term with factors such as CNTF to induce GFAP
Remove adherent non-neural cells via astrosphere culture method (Krencik and
Zhang, 2011)
Mature astrocytes Identification of mature vs. immature
Identification of mature vs. reactive Not yet well-defined. Conduct quantitative measurement of GFAP and other
markers over time
Functional characterization Not yet well-defined
Recommended assays include proliferation, synaptogenic studies with neuron
cocultures, receptor/transporter stimulation followed by electrophysiological
measurements or calcium imaging (Krencik et al., 2011), BBB
formation/maintenance of endothelia
Engrafted astrocytes Test for functional integration Measure: Glutamate uptake after synaptic stimulation
Calcium wave propagation between endogenous and engrafted human astrocytes
Endfeet formation on blood vessels, constriction assay after stimulation
Rescue a mouse disease model
Diseased states Determine disease-specific phenotype Assay for known disease-related phenotype in monoculture, coculture, or
post-engraftment
Profile at various levels for reactive signature
Rescue the phenotype Screen pharmacological or genetic (siRNA, etc.) methods
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diseases, it would be more feasible to inject or overlay hPSC-
derived astrocytes into rodent slice cultures to allow functional
integration followed by characterization with electrophysiolog-
ical recordings, as has been conducted with mouse stem cell-
derived glial progenitors (Scheffler et al., 2003; Husseini et al.,
2008). For example, this coculture system has been utilized with
hPSC-derived neurons in order to measure their resultant neu-
ronal orientation and differentiation over time (Shi et al., 2012).
Better yet, cells can be directly transplanted into a live ani-
mal for long term functional integration as has been previously
conducted (Weick et al., 2011). What functional measurements
would be informative after engraftment of human astrocytes into
the rodent nervous system? Potential measurements could include
the response of diseased astrocytes to synaptic activity via glu-
tamate uptake measurements (Bergles and Jahr, 1998) or while
calcium imaging during different experimental paradigms (Duffy
and MacVicar, 1995; Torres et al., 2012), interactions with brain
vasculature (Mulligan and MacVicar, 2004; Krencik et al., 2011),
or the response of adjacent neurons after astrocyte stimulation
with optogenetic tools (Figueiredo et al., 2011; Sasaki et al., 2012).
Besides investigating questions about diseases, this system could
also be used for regenerative medicine. For example, human
astrocytes may be used as neuroprotective tools by transplanting
them into a diseased system (Lepore et al., 2008) or as vehicles to
deliver neurotrophic compounds (Drinkut et al., 2012).
CONCLUSIONS
Astrocyte differentiation includes most of the same advantages
and drawbacks that exist when generating heterogenous neural
and non-neural cell types from hPSCs, although as described
above they have additional technical challenges that include an
extensive developmental timeline, limited cell specific tools, and
sensitivity to stressful stimulations that leads to reactive astroglio-
sis. By summarizing these challenges and the best techniques with
which to meet them (Table 1), this review can be used as an atlas
to accordingly plan studies to produce the best model system pos-
sible, while keeping efforts of the researchers at a minimum.With
careful preparation, functional analysis of astrocytes during dis-
ease studies can be conducted with high standards to account
for cellular and temporal heterogeneity, although understandably
most studies cannot address all the issues listed above. Typically,
neurodevelopmental diseases such as RASopathies and neurode-
generative diseases have been modeled using neuronal cell types,
but the roles of astrocytes in other less studied pathologies may
also be targeted such as neuropathic pain (Watkins and Maier,
2003), sleep, and memory (Ben Achour and Pascual, 2012).
Future technologies including high throughput screens, robotic
apparatuses, computer models, and improved data analysis pro-
grams will undoubtedly increase the scale and accuracy of data
collection/interpretation. Together with improved techniques to
image and monitor healthy and diseased human astrocytes in
culture or engrafted into a donor nervous system, the poten-
tial for glial studies in regenerative medicine and future disease
discoveries can reach to the stars.
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